Relcovaptan: a promising therapeutic agent in traumatic spinal cord injury that acts by modulating newly identified transcriptional regulators of aquaporins compared to tolvaptan
Our study suggests that clinical application of relcovaptan may be a promising treatment option for improving tSCI.
Authors
- Şeyma İş (ORCID: https://orcid.org/0000-0002-5151-6758)
- ŞABAN TEKİN
- MERİH İŞ
- DUYGU CEMAN
- NEŞE KESER
Institutions
- Türkisch-Deutsche Universität (TR)
- Haydarpaşa Numune Eğitim ve Araştırma Hastanesi (TR)
- Sağlık Bilimleri Üniversitesi (TR)
- Fatih Sultan Mehmet Eğitim Ve Araştırma Hastanesi (TR)
- University of Health Sciences Antigua (AG)
Publication Details
- Journal
- TURKISH JOURNAL OF MEDICAL SCIENCES
- Published
- 2025-12-12
- DOI
- https://doi.org/10.55730/1300-0144.6097
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00